Why Are People Talking About Investing in EXAS?

By Tamara Parker • Thursday, September 21 10:17 • Permanent Link

Join us for a quick overview of Exact Sciences, a Medical Specialities company whose shares moved -1.7% today. Here are some facts about the stock that should help you see the bigger picture:

Exact Sciences has moved 109.0% over the last year, and the S&P 500 logged a change of 17.0%
EXAS has an average analyst rating of buy and is -35.64% away from its mean target price of $111.47 per share
Its trailing earnings per share (EPS) is $-2.34
Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -30.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.08 and its forward P/E ratio is -66.4
The company has a Price to Book (P/B) ratio of 4.24 in contrast to the S&P 500's average ratio of 2.95
Exact Sciences is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-62333248, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.